About this FactMed analysis covering adverse side effect reports of TEBETANE COMPUESTO patients who developed EXTRAPYRAMIDAL DISORDER.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking TEBETANE COMPUESTO reported EXTRAPYRAMIDAL DISORDER to the FDA. A total of 13 TEBETANE COMPUESTO drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between TEBETANE COMPUESTO and EXTRAPYRAMIDAL DISORDER. In doing so, we compare TEBETANE COMPUESTO with other drugs that cause EXTRAPYRAMIDAL DISORDER, to help you evaluate whether or not TEBETANE COMPUESTO causes EXTRAPYRAMIDAL DISORDER. Likewise, this page shows the most highly-reported side effects of TEBETANE COMPUESTO, so you can see if EXTRAPYRAMIDAL DISORDER ranks among TEBETANE COMPUESTO's most well-known side effects.
Summary Statistics
Reports of TEBETANE COMPUESTO causing EXTRAPYRAMIDAL DISORDER: 1
Reports of any side effect of TEBETANE COMPUESTO : 13
Percentage of TEBETANE COMPUESTO patients where EXTRAPYRAMIDAL DISORDER is a reported side effect: 7.6923%

FDA reports of any drug causing EXTRAPYRAMIDAL DISORDER : 18150
Average percentage for all medicated patients where EXTRAPYRAMIDAL DISORDER is reported as a complication: 0.1138%

Physician opinion on TEBETANE COMPUESTO as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing TEBETANE COMPUESTO:
PROSTATISM ( 4 patients )
BENIGN PROSTATIC HYPERPLASIA ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with EXTRAPYRAMIDAL DISORDER:

METOCLOPRAMIDE (19661 patients)
REGLAN (4979 patients)
RISPERDAL (925 patients)
SEROQUEL (649 patients)
METOCLOPRAMIDE HYDROCHLORIDE (644 patients)
HALOPERIDOL (619 patients)
ABILIFY (453 patients)
RISPERIDONE (416 patients)
ZYPREXA (390 patients)
GEODON (285 patients)
RISPERDAL CONSTA (283 patients)
HALDOL (274 patients)
LORAZEPAM (246 patients)
INVEGA (234 patients)
ASPIRIN (228 patients)
OLANZAPINE (196 patients)
NEXIUM (185 patients)
OMEPRAZOLE (162 patients)
DEPAKOTE (158 patients)
CLOZAPINE (157 patients)
ZOLOFT (154 patients)
CITALOPRAM HYDROBROMIDE (148 patients)
CLONAZEPAM (146 patients)
LITHIUM CARBONATE (145 patients)
DIAZEPAM (143 patients)
PAXIL (138 patients)
PROZAC (135 patients)
NEURONTIN (134 patients)
ALPRAZOLAM (134 patients)
XANAX (118 patients)
LISINOPRIL (112 patients)
LAMICTAL (110 patients)
EFFEXOR (107 patients)
PROTONIX (106 patients)
PRILOSEC (106 patients)
CLOZARIL (105 patients)
LIPITOR (105 patients)
LEXAPRO (104 patients)
FUROSEMIDE (103 patients)
HALOPERIDOL DECANOATE (102 patients)
COGENTIN (101 patients)
VALPROATE SODIUM (101 patients)
MIRTAZAPINE (100 patients)
GABAPENTIN (99 patients)
CYMBALTA (99 patients)
LYRICA (99 patients)
PREV MEDS (98 patients)
SIMVASTATIN (98 patients)
PROMETHAZINE (98 patients)
HYDROCHLOROTHIAZIDE (94 patients)
INVEGA SUSTENNA (93 patients)
ARICEPT (93 patients)
TRAZODONE HCL (92 patients)
CON MEDS (90 patients)
ACETAMINOPHEN (90 patients)
PLAVIX (89 patients)
ATIVAN (89 patients)
NITROGLYCERIN (88 patients)
BENADRYL (87 patients)
DEPAKENE (87 patients)
METOCLOPRAMIDE TABLETS USP, 10 MG (PUREPAC) (87 patients)
FLUOXETINE (86 patients)
VIOXX (86 patients)
LASIX (84 patients)
PREVACID (83 patients)
METOCLOPRAMIDE HCL (83 patients)
ALBUTEROL (81 patients)
AMBIEN (81 patients)
LEVAQUIN (80 patients)
ARIPIPRAZOLE (80 patients)
ESCITALOPRAM (80 patients)
LEVOTHYROXINE SODIUM (79 patients)
PREDNISONE (79 patients)
WELLBUTRIN (78 patients)
CELEXA (77 patients)
AMITRIPTYLINE HCL (74 patients)
KLONOPIN (74 patients)
CELEBREX (73 patients)
AMOXICILLIN (72 patients)
ZOCOR (71 patients)
FOLIC ACID (71 patients)
VALIUM (71 patients)
QUETIAPINE (71 patients)
CLONIDINE (70 patients)
ZOFRAN (70 patients)
QUETIAPINE FUMARATE (70 patients)
ZOLPIDEM (69 patients)
TRAMADOL HCL (69 patients)
IBUPROFEN (66 patients)
LEPONEX (66 patients)
SAPHRIS (66 patients)
METFORMIN HCL (66 patients)
AMLODIPINE (64 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (64 patients)
INSULIN (64 patients)
ACE INHIBITORS (63 patients)
ATENOLOL (63 patients)
MIRAPEX (63 patients)
SINGULAIR (62 patients)
LIPID LOWERING THERAPY (62 patients)
POTASSIUM CHLORIDE (62 patients)
LANTUS (62 patients)
PAROXETINE HCL (62 patients)
OXYCODONE HCL (61 patients)
CEPHALEXIN (61 patients)
LITHIUM (60 patients)
NORVASC (60 patients)
VICODIN (59 patients)
ZITHROMAX (59 patients)
SERTRALINE HYDROCHLORIDE (57 patients)
AKINETON (57 patients)
LAMOTRIGINE (57 patients)
CIPROFLOXACIN (57 patients)
ZANTAC (57 patients)
TOPAMAX (56 patients)
EXELON (54 patients)
TOPROL-XL (54 patients)
METOPROLOL TARTRATE (54 patients)
SINEMET (54 patients)
TEMAZEPAM (53 patients)
PREMARIN (53 patients)
OXAZEPAM (51 patients)
BIPERIDEN HYDROCHLORIDE TAB (51 patients)
FOSAMAX (50 patients)
TERCIAN (49 patients)
BACLOFEN (49 patients)
COUMADIN (49 patients)
PROPRANOLOL (48 patients)
ATARAX (48 patients)
REQUIP (47 patients)
CLINDAMYCIN (47 patients)
VALPROIC ACID (46 patients)
TEGRETOL (46 patients)
RIVOTRIL (46 patients)
REMERON (45 patients)
FLEXERIL (45 patients)
AMISULPRIDE (45 patients)
RANITIDINE (44 patients)
ZYRTEC (44 patients)
OXYCONTIN (44 patients)
PROCYCLIDINE HYDROCHLORIDE 2MG TAB (43 patients)
ORAL HYPOGLYCAEMICS (42 patients)
FAMOTIDINE (42 patients)
SYNTHROID (42 patients)
DARVOCET (42 patients)
ELAVIL (41 patients)
EFFEXOR XR (41 patients)
PANTOPRAZOLE (41 patients)
CRESTOR (41 patients)
FERROUS SULFATE TAB (40 patients)
FLUCONAZOLE (40 patients)
NOZINAN (40 patients)
PREDNISOLONE (40 patients)
MECLIZINE (40 patients)
SEROQUEL XR (39 patients)
IMOVANE (39 patients)
BENZTROPINE MESYLATE (39 patients)
PERCOCET (38 patients)
CORDARONE (38 patients)
VITAMIN D (38 patients)
ALLOPURINOL (38 patients)
ONDANSETRON (37 patients)
AUGMENTIN '125' (37 patients)
MORPHINE (36 patients)
PALIPERIDONE (36 patients)
FENTANYL (36 patients)
PAROXETINE (36 patients)
VITAMIN B-12 (36 patients)
FLOMAX (36 patients)
NAPROXEN (35 patients)
DEROXAT (35 patients)
KEPPRA (35 patients)
TEMESTA (35 patients)
MEMANTINE HCL (35 patients)
CITALOPRAM (35 patients)
FLONASE (35 patients)
SOLIAN (35 patients)
CONCERTA (34 patients)
DIGOXIN (34 patients)
HYDROCODONE (34 patients)
ENALAPRIL MALEATE (34 patients)
ACIPHEX (34 patients)
ADVAIR DISKUS 100/50 (34 patients)
AZITHROMYCIN (34 patients)
DIPHENHYDRAMINE HCL (34 patients)
LEPTICUR (33 patients)
KLOR-CON (33 patients)
CARBAMAZEPINE (33 patients)
THORAZINE (33 patients)
ERGENYL (33 patients)
COLACE (33 patients)
NYSTATIN (33 patients)
LANSOPRAZOLE (33 patients)
MIRALAX (33 patients)
GLUCOPHAGE (32 patients)
LOVENOX (32 patients)
RITALIN (32 patients)
PREDNISONE TAB (31 patients)
MOTRIN (31 patients)
METRONIDAZOLE (31 patients)
MULTI-VITAMIN (31 patients)
LORTAB (31 patients)
ZOLPIDEM TARTRATE (31 patients)
NASONEX (31 patients)
COZAAR (30 patients)
ULTRAM (30 patients)
VITAMIN E (30 patients)
CYCLOBENZAPRINE (30 patients)
ERYTHROMYCIN (29 patients)
MUCINEX (29 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for TEBETANE COMPUESTO


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about EXTRAPYRAMIDAL DISORDER and TEBETANE COMPUESTO, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking TEBETANE COMPUESTO, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in TEBETANE COMPUESTO. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for TEBETANE COMPUESTO experts. If you are a healthcare provider experienced in prescribing TEBETANE COMPUESTO, please register here.
© 2014 FactMed, Inc
Privacy Policy
Terms of Use